Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings
Executive Summary
Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor
You may also be interested in...
Pfizer/Pharmacia Will Start With $39 Bil. In Worldwide Rx Sales
Pfizer/Pharmacia will begin operations with baseline annual worldwide pharmaceutical sales of approximately $39 bil., based on an analysis of the companies' 2002 year-end results
Pfizer/Pharmacia Will Start With $39 Bil. In Worldwide Rx Sales
Pfizer/Pharmacia will begin operations with baseline annual worldwide pharmaceutical sales of approximately $39 bil., based on an analysis of the companies' 2002 year-end results
Bextra “Dear Doctor” letter
Pfizer/Pharmacia send "Dear Doctor" letter Nov. 13 alerting physicians to new warnings and a contraindication in Bextra labeling against use in patients with demonstrated allergic-type reactions to sulfonamides. The companies first alerted prescribers to the issue in October; revised labeling was approved by FDA Nov. 1 (1"The Pink Sheet" Nov. 11, p. 19)...